Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1088614 | 0.85 | SPHK1 (0.47) | TDP1SPHK1 | |
| SCHEMBL1100128 | 0.84 | SPHK1 (0.49) | TDP1SPHK1 | |
| SCHEMBL1088319 | 0.83 | SPHK1 (0.42) | TDP1SPHK1CTSK | |
| SCHEMBL29060117 | 0.81 | SPHK1 (0.33) | SPHK1CTSK | |
| Iodide SCHEMBL7205304 | 0.80 | SPHK1 (0.33) | SPHK1CTSK | |
| SCHEMBL7205303 | 0.80 | SPHK1 (0.33) | SPHK1CTSK | |
| SCHEMBL15418650 | 0.79 | CTSK (0.36) | SPHK1CTSK | |
| SCHEMBL18180487 | 0.79 | CYP4A11 (0.33) | TDP1CYP4F2CYP4A11 | |
| SCHEMBL1089166 | 0.79 | SPHK1 (0.35) | SPHK1CTSK | |
| SCHEMBL27014757 | 0.78 | CTSK (0.35) | TDP1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527853-B2 | Fused triazole derivatives as gamma secretase modulators | ARES TRADING S.A. (CH) | 2016-12-27 | — | — | US | disclosed |
| US-9527853-B2 | Fused triazole derivatives as gamma secretase modulators | ARES TRADING S.A. (CH) | 2016-12-27 | — | — | US | disclosed |
| EP-2875025-B1 | FUSED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ARES TRADING SA (CH) | 2016-11-30 | — | — | EP | disclosed |
| US-20150183790-A1 | FUSED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | MERCK PATENT GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-20150183790-A1 | FUSED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | MERCK PATENT GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| EP-2687528-A1 | Fused triazole derivatives as gamma secretase modulators | ARES TRADING S.A. (CH) | 2014-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183790-A1 | FUSED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, GSAP, BACE2 | TDP1 1272/4885SPHK1 2091/4885CYP4F2 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.